A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.

ABSTRACT:

Objective

To investigate the preliminary safety and efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, for atopic dermatitis.

Design

This investigator-initiated, open-label pilot study evaluated 2 doses of apremilast in patients with atopic dermatitis. Differential gene analysis was performed from peripheral whole blood using data before and after treatment.

Setting

University-based dermatology clinical research unit.

Patients

Sixteen adult patients with atopic dermatitis.

Intervention

A specific phosphodiesterase 4 inhibitor, apremilast.

Main outcome measures

The primary outcome was incidence of adverse events. Secondary outcomes included the differences in pruritus, Dermatology Life Quality Index (DLQI), and Eczema Area and Severity

SUBMITTER: Samrao A 

PROVIDER: S-EPMC3614494 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature